DDInter624 DDInter631
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood. Eltrombopag has also been recently approved (late 2012) for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy.
Efavirenz {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Eltrombopag
Efavirenz {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Boceprevir
Boceprevir {u} may cause a minor interaction that can limit clinical effects when taken with {v} Eltrombopag
Efavirenz {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Lopinavir
Lopinavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eltrombopag
Efavirenz {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A4 Inhibitors
Cytochrome P450 3A4 Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Boceprevir
Boceprevir {u} may cause a minor interaction that can limit clinical effects when taken with {v} Eltrombopag
Efavirenz {u} (Compound) causes {v} (Side Effect) Feeling abnormal
Feeling abnormal {u} (Side Effect) is caused by {v} (Compound) Boceprevir
Boceprevir {u} may cause a minor interaction that can limit clinical effects when taken with {v} Eltrombopag
Efavirenz {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A4 Inhibitors
Cytochrome P450 3A4 Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Simeprevir
Simeprevir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eltrombopag
Efavirenz {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Simeprevir
Simeprevir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eltrombopag
Efavirenz {u} (Compound) causes {v} (Side Effect) Feeling abnormal
Feeling abnormal {u} (Side Effect) is caused by {v} (Compound) Simvastatin
Simvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eltrombopag
Efavirenz {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A4 Inhibitors
Cytochrome P450 3A4 Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Lomitapide
Lomitapide {u} may lead to a major life threatening interaction when taken with {v} Eltrombopag
Efavirenz {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Leflunomide
Leflunomide {u} may lead to a major life threatening interaction when taken with {v} Eltrombopag
Efavirenz (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Eltrombopag (Compound)
Efavirenz (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Boceprevir (Compound) and Boceprevir may cause a minor interaction that can limit clinical effects when taken with Eltrombopag
Efavirenz (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Lopinavir (Compound) and Lopinavir may cause a moderate interaction that could exacerbate diseases when taken with Eltrombopag
Efavirenz (Compound) is included by Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) and Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) includes Boceprevir (Compound) and Boceprevir may cause a minor interaction that can limit clinical effects when taken with Eltrombopag
Efavirenz (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Boceprevir (Compound) and Boceprevir may cause a minor interaction that can limit clinical effects when taken with Eltrombopag
Efavirenz (Compound) is included by Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) and Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) includes Simeprevir (Compound) and Simeprevir may cause a moderate interaction that could exacerbate diseases when taken with Eltrombopag
Efavirenz (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Simeprevir (Compound) and Simeprevir may cause a moderate interaction that could exacerbate diseases when taken with Eltrombopag
Efavirenz (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Simvastatin (Compound) and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Eltrombopag
Efavirenz (Compound) is included by Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) and Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) includes Lomitapide (Compound) and Lomitapide may lead to a major life threatening interaction when taken with Eltrombopag
Efavirenz (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Leflunomide (Compound) and Leflunomide may lead to a major life threatening interaction when taken with Eltrombopag